Zoetis Inc. (ZTS) stock
ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 17/3046% below fair value
$83.48−0.91 (-1.08%)
Close on Nov 17, 2026Market cap $34.50BP/E 13.7Yield 2.43%
Zoetis r&d expenses
Research and development expenses are spending on new products and technology.
Zoetis's R&D Expenses for the twelve months ending Jun 30, 2026 was $722.00M, up 6.0% year over year. For fiscal 2025 it was $698.00M, up 1.7% from the year before. Over ten years it grew 6.7% a year on average. The highest annual figure on record is $698.00M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $698.00M | +1.7% |
| FY2024 | Dec 31, 2024 | $686.00M | +11.7% |
| FY2023 | Dec 31, 2023 | $614.00M | +13.9% |
| FY2022 | Dec 31, 2022 | $539.00M | +6.1% |
| FY2021 | Dec 31, 2021 | $508.00M | +9.7% |
| FY2020 | Dec 31, 2020 | $463.00M | +1.3% |
| FY2019 | Dec 31, 2019 | $457.00M | +5.8% |
| FY2018 | Dec 31, 2018 | $432.00M | +13.1% |
| FY2017 | Dec 31, 2017 | $382.00M | +1.6% |
| FY2016 | Dec 31, 2016 | $376.00M | +3.3% |
| FY2015 | Dec 31, 2015 | $364.00M | -8.1% |
| FY2014 | Dec 31, 2014 | $396.00M | -0.8% |
| FY2013 | Dec 31, 2013 | $399.00M | -2.4% |
| FY2012 | Dec 31, 2012 | $409.00M | -4.2% |
| FY2011 | Dec 31, 2011 | $427.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $173.00M | +4.2% |
| Q1 FY2026 | Mar 31, 2026 | $180.00M | +11.1% |
| Q4 FY2025 | Dec 31, 2025 | $199.00M | +7.0% |
| Q3 FY2025 | Sep 30, 2025 | $170.00M | +1.8% |
| Q2 FY2025 | Jun 30, 2025 | $166.00M | -2.9% |
| Q1 FY2025 | Mar 31, 2025 | $162.00M | 0.0% |
| Q4 FY2024 | Dec 31, 2024 | $186.00M | +6.9% |
| Q3 FY2024 | Sep 30, 2024 | $167.00M | +9.9% |
| Q2 FY2024 | Jun 30, 2024 | $171.00M | +17.1% |
| Q1 FY2024 | Mar 31, 2024 | $162.00M | +14.1% |
| Q4 FY2023 | Dec 31, 2023 | $174.00M | +17.6% |
| Q3 FY2023 | Sep 30, 2023 | $152.00M | +13.4% |
| Q2 FY2023 | Jun 30, 2023 | $146.00M | +8.1% |
| Q1 FY2023 | Mar 31, 2023 | $142.00M | +16.4% |
| Q4 FY2022 | Dec 31, 2022 | $148.00M | +7.2% |
| Q3 FY2022 | Sep 30, 2022 | $134.00M | +1.5% |
| Q2 FY2022 | Jun 30, 2022 | $135.00M | +12.5% |
| Q1 FY2022 | Mar 31, 2022 | $122.00M | +3.4% |
| Q4 FY2021 | Dec 31, 2021 | $138.00M | +3.8% |
| Q3 FY2021 | Sep 30, 2021 | $132.00M | +17.9% |
| Q2 FY2021 | Jun 30, 2021 | $120.00M | +8.1% |
| Q1 FY2021 | Mar 31, 2021 | $118.00M | +10.3% |
| Q4 FY2020 | Dec 31, 2020 | $133.00M | +0.8% |
| Q3 FY2020 | Sep 30, 2020 | $112.00M | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | $111.00M | 0.0% |
| Q1 FY2020 | Mar 31, 2020 | $107.00M | +4.9% |
| Q4 FY2019 | Dec 31, 2019 | $132.00M | +5.6% |
| Q3 FY2019 | Sep 30, 2019 | $112.00M | +3.7% |
| Q2 FY2019 | Jun 30, 2019 | $111.00M | +8.8% |
| Q1 FY2019 | Mar 31, 2019 | $102.00M | +5.2% |
| Q4 FY2018 | Dec 31, 2018 | $125.00M | +13.6% |
| Q3 FY2018 | Sep 30, 2018 | $108.00M | +12.5% |
| Q2 FY2018 | Jun 30, 2018 | $102.00M | +18.6% |
| Q1 FY2018 | Mar 31, 2018 | $97.00M | +7.8% |
| Q4 FY2017 | Dec 31, 2017 | $110.00M | +1.9% |
| Q3 FY2017 | Oct 1, 2017 | $96.00M | +6.7% |
| Q2 FY2017 | Jul 2, 2017 | $86.00M | – |
| Q1 FY2017 | Apr 2, 2017 | $90.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $108.00M | – |
| Q3 FY2016 | Oct 2, 2016 | $90.00M | – |
See a number that looks wrong?